Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.

Slides:

Advertisements

Similar presentations

Long-term outcome of patients in the LNH-98

Advertisements

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia by Nathalie Dhédin, Anne Huynh, Sébastien.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

HS 4160 Critical Scientific Analysis

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Secondary or Concomitant Neoplasms among Adults Diagnosed with Acute Lymphoblastic Leukemia (ALL) and Treated According to the LALA-87 and LALA-94 Trials.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Gupta V, Tallman MS, Weisdorf DJ

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML by Nona Shayegi, Michael Kramer,

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results by Lionel Adès, Miguel A. Sanz,

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation Kazuko.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3- ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

Killer Cell Immunoglobulin-Like Receptor–Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Aline Clavert, Zinaida Peric, Eolia.

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

How I treat refractory and early relapsed acute myeloid leukemia

by Jan J. Cornelissen, and Didier Blaise

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Balancing bleeding in brain metastases

Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic.

Presentation transcript:

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry Leblanc, Pierre Fenaux, Françoise Rigal-Huguet, Francis Witz, Thierry Lamy, Anne Auvrignon, Didier Blaise, Arnaud Pigneux, Francine Mugneret, Christian Bastard, Nicole Dastugue, Jacqueline Van den Akker, Denis Fière, Josy Reiffers, Sylvie Castaigne, Guy Leverger, Jean-Luc Harousseau, and Hervé Dombret Blood Volume 102(2):462-469 July 15, 2003 ©2003 by American Society of Hematology

Prognostic impact of age on outcome of CR patients. Prognostic impact of age on outcome of CR patients. (A) DFS. (B) Cumulative incidence of relapse. Jacques Delaunay et al. Blood 2003;102:462-469 ©2003 by American Society of Hematology

Prognostic impact of allogeneic HSCT versus chemotherapy on outcome of CR patients up to 50 years of age (intent-to-treat analysis). Prognostic impact of allogeneic HSCT versus chemotherapy on outcome of CR patients up to 50 years of age (intent-to-treat analysis). (A) DFS. (B) Overall survival of CR patients. Jacques Delaunay et al. Blood 2003;102:462-469 ©2003 by American Society of Hematology

Prognostic impact of the postremission chemotherapy (IDAC versus HDAC) on outcome of CR patients (intent-to-treat analysis). Prognostic impact of the postremission chemotherapy (IDAC versus HDAC) on outcome of CR patients (intent-to-treat analysis). (A) DFS. (B) Cumulative incidence of death in CR. Jacques Delaunay et al. Blood 2003;102:462-469 ©2003 by American Society of Hematology

Comparative evaluation of age and WBC prognostic significance in t(8;21) and inv(16)/t(16;16) AML. (A) Adjusted P values for DFS according to selected age cutpoints. Comparative evaluation of age and WBC prognostic significance in t(8;21) and inv(16)/t(16;16) AML. (A) Adjusted P values for DFS according to selected age cutpoints. (B) Adjusted P values for DFS according to selected WBC cutpoints. P values for DFS comparison, after adjustment based on an approximation to the improved Bonferroni inequality,16 are given according to selected age (A) and WBC (B) cutpoints in each CBF-AML subtype. In inv(16)/t(16;16) AML, the optimal age cutpoint was 35 years (adjusted P value = .001). In t(8;21) AML, the optimal WBC cutpoint was 30 × 109/L (adjusted P value = .014). Jacques Delaunay et al. Blood 2003;102:462-469 ©2003 by American Society of Hematology